肺癌1号方加减治疗肺癌术后化疗后患者的疗效观察

Efficacy of Feiaifang No.1 (肺癌1号方) Variation on Lung Cancer after Surgery and Chemotherapy

目的:观察肺癌1号方加减治疗肺癌术后化疗后患者的临床疗效。方法:收集94例肺癌术后化疗后患者,予肺癌1号方治疗,治疗3个月后观察KPS评分、证候积分,评价疗效。结果:治疗后KPS评分平均(74.89±9.91)分,高于治疗前(P<0.05);生活质量改善有效率为83.8%;治疗后临床证候积分为(2.40±2.11)分,低于治疗前(P<0.05);症状改善率为69.0%。治疗后1年生率为70.7%,两年生存率为29.4%。结论:肺癌1号方加减治疗肺癌术后化疗后患者具有一定疗效,能改善临床症状、提高患者生活质量。

Objective： To observe efficacy of Feiaifang No.1 variation on lung cancer after surgery and chemotherapy. Methods：The 94 cases of patients with lung cancer ＇after surgery and chemotherapy were treated by Feiaifang No.1. The Karnofsky and symptom scores were observed in 3 months, and the efficacy was evalu- ated. Results： The Karnofsky score was （74.89±9.914） points after treatment, which was higher than before treat- ment （P〈0.05）; The life quality effective rate was 83.8%; the main clinical symptom score was （2.4±2.11） points after treatment, which was lower than before treatment （P〈0.05）; The symptom improvement rate was 69.0%. The one-year survival rate was 70.7%, and two-year survival rate was 29.4%. Conclusion： The Feiaifang No.1 varia- tion showed certain efficacy on lung cancer after surgery and chemotherapy; It can relieve clinical symptoms and improve quality of life.